Trials / Terminated
TerminatedNCT05394350
A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)
A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will evaluate the safety, tolerability, and pharmacokinetics (PK) of MK-1088 in monotherapy and in combination with pembrolizumab in participants with advanced solid tumors who have not responded to conventional therapy. The effect of MK-1088 on tumor size will also be examined.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-1088 | Oral Tablet |
| BIOLOGICAL | Pembrolizumab | IV Infusion |
Timeline
- Start date
- 2022-07-07
- Primary completion
- 2023-09-07
- Completion
- 2023-09-07
- First posted
- 2022-05-27
- Last updated
- 2024-11-08
- Results posted
- 2024-10-04
Locations
13 sites across 5 countries: United States, Canada, Denmark, Israel, Switzerland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05394350. Inclusion in this directory is not an endorsement.